Biogen
Statements
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
This unprecedented CMS decision effectively denies all Medicare beneficiaries access to ADUHELM® (aducanumab-avwa), the first and only FDA-approved therapy in a new class of Alzheimer’s drugs. It may also limit coverage for any future approved treatment in the class.
The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper
The National Minority Quality Forum (NMQF) and Biogen will today discuss the importance of generating real-world evidence on a webinar hosted by NMQF on equitable access to research and care. Together, the organizations have also issued a white paper highlighting how real-world evidence (RWE) is
Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease
Biogen Response to CMS
Biogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
Alzheimer’s patients and their families deserve to have choice and access to FDA-approved treatments. Biogen believes that the proposed coverage with evidence development (CED) decision for anti-amyloid therapies denies nearly all Medicare beneficiaries from accessing ADUHELM® (aducanumab-avwa) 100
Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa).
A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It’s Time for Companies to Act Like the Climate Crisis is a Health Crisis
Right now, delegations are descending upon Glasgow for the 26th annual United Nations Climate Change Conference (COP26) – with more than 100 world leaders gathering to accelerate climate action to meet goals set by the Paris Agreement and the UN Framework Convention on Climate Change.
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
September 23, 2021 – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil
Biogen and Eisai Update for the Alzheimer’s Disease Community
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021, ADUHELM™ (aducanumab-avwa) 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration (FDA). We are committed to responding to questions from the Alzheimer’s disease community and providing more details about our plans.
A Letter from Biogen’s CEO on ADUHELM
Today, on behalf of my Biogen colleagues, I am incredibly humbled to share that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELMTM (aducanumab-avwa), the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque. We come
Biogen Statement about Director and Chair of the Compensation and Management Development Committee Robert W. Pangia
Robert W. Pangia, who has served as a Biogen director since 1997, will retire from the company’s Board this year, effective at the annual meeting of stockholders. Biogen and the Board of Directors would like to thank Bob for his decades-long service and invaluable support.